General Updates

Ref: ISLL:CH:2026 Date: 12th October, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB Subject: Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 Dear Sir/Ma’am, Please find enclosed herewith disclosures received under Regulation 29(2) of SEBI (Substantial acquisition of Shares and Takeover) Regulations, 2011 received by the Company on 12th October, 2026 from Essix Biosciences Limited. You are requested to take the same on your record. With Regards, For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Essm B|03C|ences Limited ~160101( INDIA] A, 2736294 Date: October 12, 2026 To, To, The Listing Compliance Department The Listing Compliance Department, National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, P. J. Tower, Dalal Street Bandra (East), Mumbai - 400051 Mumbai — 400001 Symbol: INDSWFTLAB Serip Code: 532305 Subject : Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dear Sir/Madam, With reference to the captioned subject, I, Himanshu Jain, Director on behalf of Essix Biosciences Limited ("Acquirer"), belonging to the Promoter and Promoter Group of Ind-Swift Laboratories Limited ("Target Company"), along with Gopal Munjal, Himanshu Jain, Navrattan Munjal, Rishav Mehta, S.R. Mehta, V.R. Mchta, Annie Mehta, Bhanavi Melta, Divya Munjal, Ishav Mehta, Meenakshi Mehta, Neeta Munjal, Nidhi Munjal, Ravi Mehta, Sahil Munjal, Sunita Jain, Saurabh Munjal, Deepti Munjal & Daksh Mehta (hereinafter collectively referred to as "PACs") hereby inform your good office that the Acquirer, has acquired 14,00,000 (Fourteen Lakh) Equity Shares pursuant to the conversion of Fully Convertible Warrants having face value of Rs. 10/ each of the Target Company on October 08, 2026 into Equity Shares. In this regard, please find enclosed the disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, by Essix Biosciences Limited, on behalf of the whole Promoter & Promoter group of the Company. You are requested to take the same on records. Thanking You, Yours Smcerely, CcC: The Board of Directors Ind-Swift Laboratories Limited SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh, 160101, India Essm Blosclences lelted Disclosures under Reg. 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 Name of the Target Company (TC) Ind- Swift Lahoratories Limited Names of the Acquirer and Person Acting in Concert Essix B ences Limited (PAC) with the Acquirer (“Acquirer™) Gopal Munjal; Himanshu Jain; o Navrattan Munjal; Rishav Mehta; S.R. Mehta; S V.R. Mehta; Annie Mehta; l Bhanavi Mehta; L Divya Munjal; s Ishav Mehta; . Meenakshi Mehta; E. Necta Munjal; B. Nidhi Munjal; 14. Ravi Mehta; 15. Sahil Munjal; 16. Sunita Jain; 17. Saurabh Munjal; 18. Deepti Munjal; & 19. Daksh Mehta (hereinafter collectively referred to as “PACs”) Whether the acquirers belong to Promoter/ Promoter Yes group Name(s) of the Stock Exchange(s) where the shares of TC 1. National Stock Exchange of India Limited are Listed (“NSE”) and 2. BSE Limited (“BSE”) Details of the acquisition as follows Number of | % w.r.t. total | % w.r.t. total Shares share/voting diluted share/ capital voting capital wherever of the TC applicable Before the acquisition under consideration, holding of: a) Shares carrying voting rights * Essix Biosciences Limited 3,28,82,521 37.81 35.00 = PAGCs 44,51,757 5.12 4.74 b) Shares in the nature of encumbrance 0 0.00 0.00 ©) Voting rights (VR) otherwise than by shares 0 0.00 0.00 d) Warrants /convertible securities/any other instrument that 0 0.00 0.00 entitles the acquirer to receive shares catrying voting rights in the TC acquired/sold = Essix Biosciences Limited I£7e80 L MA \ 70,00,000 - 7.45 Total (at+b+c+d) g \ 4,43,34,278 42.93 47.18 Details of acquisition: a) Shares carrying voting rights acquired/seld = Essix Biosciences Limited 14,00,000 1.58 149 b) Shares in the nature of encumbrance 0 0.00 0.00 ©) Voting rights (VR) otherwise than by shares 0 0.00 0.00 d) Warrants /convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC acquiredseld Total (a+b+e+d) 14,00,000 1.58 1.49 After the acquisition/sale, holding of: a) Shares carrying voling rights ® Essix Biosciences Limited 3,42,82,521 38.80 36.48 ®= PACs 44,51,757 5.04 4.74 b) Shares in the nature of encumbrance 0 0.00 0.00 c) Voting rights (VR) otherwise than by shares 0 0.00 0.00 d) Warrants /convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC acquired/seld ® Essix Biosciences Limited 56,00,000 - 5.96 Total (atb+c+d) 4,43,34,278 43.84 47.18 Mode of acquisition /sale Allotment of Fully Convertible Warrants through Preferential Issue by the Target Company. Date of receipt of intimation of allotment of shares October 08, 2026 ("Date of Allotment") Equity share capital / total voting capital of the TC before Rs. 86,96,15,580/- comprising of 8,69,61,558 the said acquisition Equity Shares of Rs. 10/- each Equity share capital/ total voting capital of the TC after Rs. 88,36,15,580/- comprising of 8,83,61,558 the said acquisition Equity Shares of Rs. 10/- each Total diluted share/voting capital of the TC after the said Rs. 93,96,15,580/- comprising of 9,39,61,558 acquisition Equity Shares of Rs. 10/- each Date: October 12, 2026